<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093426</url>
  </required_header>
  <id_info>
    <org_study_id>CLM-INS-004</org_study_id>
    <nct_id>NCT05093426</nct_id>
  </id_info>
  <brief_title>PERSONAL - Sleep In Breast Cancer</brief_title>
  <official_title>Personalised Electronic Record Supported Two-Stage Observational Study of Sleep in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Closed Loop Medicine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Closed Loop Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleep is essential for human function, immunity, and well-being. In the general population,&#xD;
      sleep disturbance and insomnia cause significant health problems and impact on the quality of&#xD;
      life of many individuals. The incidence of insomnia in cancer patients is disproportionality&#xD;
      higher, with breast cancer patients experiencing prevalence rates ranging from 19% to 69%.&#xD;
      The impact of insomnia on cancer patients' lives can be significant and is associated with&#xD;
      depression, cancer-related fatigue, increased pain, reduced quality of life, decreased&#xD;
      immunity, disease progression, and survival. To date, breast cancer studies show large&#xD;
      variation in reported insomnia prevalence rates, and the severity of sleep complaints in&#xD;
      these patients have been difficult to assess. Thus, these issues require further&#xD;
      investigation using standardised and validated measures.&#xD;
&#xD;
      In this observational study, we aim to investigate the prevalence and severity of insomnia in&#xD;
      a cohort of breast cancer patients at the Christie Hospital using the Insomnia Severity Index&#xD;
      (ISI), a validated measure for insomnia. This study will consist of two stages. In Stage 1,&#xD;
      patients aged 18 and over, who provide informed consent and have a diagnosis of Stage I, II&#xD;
      or III breast cancer in the previous 12 months will be asked to complete the validated ISI.&#xD;
      Using the ISI, participants identified as having sleeping difficulties and/or insomnia will&#xD;
      be invited to Stage 2 of the study. In this stage, participants will be asked to track their&#xD;
      sleep each morning for 3 weeks using a digital sleep diary downloaded onto their own&#xD;
      smartphone. They will also be asked to complete a series of questionnaires gathering&#xD;
      information regarding their quality of life, well-being, and health. This research will&#xD;
      provide a better understanding of sleeping patterns, sleeping difficulties and insomnia in&#xD;
      patients with breast cancer, and in the long-term, help us design better treatments for&#xD;
      patients with sleeping problems.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of insomnia in a cohort of breast cancer patients</measure>
    <time_frame>3 weeks</time_frame>
    <description>Proportion of breast cancer patients scoring 8 or above on the Insomnia Severity Index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In patients with breast cancer experiencing insomnia (defined as score of 8 or more on the Insomnia Severity Index; ISI scale), to assess insomnia severity over a three-week period.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Insomnia severity using Insomnia Severity Index (min. 0, max. 28 where higher scores mean a worse outcome). With severity classified by total score for the Insomnia Severity Index: 0-7 no significant insomnia, 8-14 Subthreshold insomnia, 15-21 Clinical insomnia (moderate severity) and 22-28 Clinical Insomnia (Severe severity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients with breast cancer experiencing insomnia (defined as score of 8 or more on the Insomnia Severity Index; ISI scale), to assess Sleep efficiency over a three-week period.</measure>
    <time_frame>3 weeks</time_frame>
    <description>Sleep efficiency (the % of time a participant is asleep whilst in bed) measured using Sleep diary (derived from total time asleep relative to total time in bed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients with breast cancer experiencing insomnia (defined as score of 8 or more on the Insomnia Severity Index; ISI scale), to assess Quality of Life over a three-week period.</measure>
    <time_frame>3 weeks</time_frame>
    <description>Quality of Life using EQ-5D-5L questionnaire (multiple choice questions regarding Mobility, Self-care, Usual activities, Pain/Discomfort and Anxiety/Depression as well as measure of % of health using scale where higher percentage is greater outcome) and Functional Assessment of Cancer Therapy - Endocrine Systems questionnaire (questions regarding Physical well-being, Social/Family well-being, Emotional, Functional well-being and Additional concerns using scale of 0 - 4 where 0 is Not at all, 1 is A little bit, 2 is Some-what, 3 is Quite a bit and 4 is Very much).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess: - Compliance of data entry into the digital sleep diary - Feasibility and experience of patients to input data relating to their sleep into a mobile phone application daily</measure>
    <time_frame>3 weeks</time_frame>
    <description>Compliance; % of patients completing sleep diary (17 or more days out of 21) Feasibility and User experience; User experience questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associations between insomnia prevalence and severity as measured by the insomnia severity index and quality of life (EQ-5D-5L and FACT-ES) with clinical or treatment characteristics of breast cancer patients.</measure>
    <time_frame>3 weeks</time_frame>
    <description>Assessment of insomnia prevalence, severity, and quality of life in subgroups based on clinical/treatment characteristics including breast cancer stage, treatment regime and baseline insomnia severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of the digital sleep diary</measure>
    <time_frame>3 weeks</time_frame>
    <description>Adverse Events and Serious Adverse Events will be collected and summarised.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">285</enrollment>
  <condition>Insomnia</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Insomnia in Breast cancer cohort</arm_group_label>
    <description>A single cohort will be observed in Stage 1 to assess the prevalence of insomnia suffered by participants who suffer from breast cancer. A subset of participants will continue to Stage 2 to use a digital sleep diary app for an observational period of 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stage 2 Digital sleep diary app</intervention_name>
    <description>Participants in Stage 2 will be asked to download a digital sleep diary app and complete a sleep log every day for 21 days.</description>
    <arm_group_label>Insomnia in Breast cancer cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A cohort of patients diagnosed with breast cancer in the United Kingdom.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Stage 1:&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  Informed consent to Stage 1 of the study&#xD;
&#xD;
          -  Diagnosis of Stage I, II or III breast cancer within the previous 12 months&#xD;
&#xD;
        Stage 2:&#xD;
&#xD;
          -  Informed consent to Stage 2 of the study&#xD;
&#xD;
          -  Current Sleep Disturbance; a score of 8 or more on the Insomnia Severity Index.&#xD;
&#xD;
          -  History of sleep disturbance prior to the screening/baseline consultation; with&#xD;
             beginning or worsening of sleep disturbance since breast cancer diagnosis e.g. sleep&#xD;
             problems began or get worse with the diagnosis of breast cancer or with chemotherapy.&#xD;
&#xD;
          -  Possession of a suitable smartphone that participant can use independently.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Stage 1:&#xD;
&#xD;
          -  Participants who have limited or no understanding of spoken and/or written English.&#xD;
&#xD;
          -  Other diagnosis of cancer, not including basal cell carcinoma of the skin or cervical&#xD;
             carcinoma in situ, within the previous 5 years&#xD;
&#xD;
        Stage 2:&#xD;
&#xD;
          -  Co-morbidities incompatible with study participation e.g. that result in a participant&#xD;
             being unable to complete daily entries satisfactorily via his/her smartphone.&#xD;
&#xD;
          -  Known and/or treated sleep apnoea&#xD;
&#xD;
          -  Regular shift work or night work (defined as &gt;1 overnight shift per month)&#xD;
&#xD;
          -  Breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Armstrong, PhD, MRCP, MBChB, BSc(Hons)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leanne Gardner, PhD</last_name>
    <phone>07500557515</phone>
    <email>leanne.gardner@closedloopmedicine.com</email>
  </overall_contact>
  <link>
    <url>https://doi.org/10.1016/j.jsmc.2013.05.002</url>
    <description>Epidemiology of Insomnia - Prevalence, Course, Risk Factors, and Public Health Burden</description>
  </link>
  <link>
    <url>http://dx.doi.org/10.1136/bmjspcare-2020-002718</url>
    <description>Insomnia in breast cancer: prevalence and associated factors</description>
  </link>
  <link>
    <url>https://doi.org/10.1093/sleep/24.5.583</url>
    <description>Prevalence, Clinical Characteristics, and Risk Factors for Insomnia in the Context of Breast Cancer</description>
  </link>
  <link>
    <url>https://doi.org/10.1093/jncics/pkz041</url>
    <description>The Relationship Between Insomnia and Cognitive Impairment in Breast Cancer Survivors</description>
  </link>
  <link>
    <url>https://doi.org/10.1108/17465721111188250</url>
    <description>Sleep as a public health concern: insomnia and mental health</description>
  </link>
  <link>
    <url>https://doi.org/10.1210/er.2015-1133</url>
    <description>The Pathophysiologic Role of Disrupted Circadian and Neuroendocrine Rhythms in Breast Carcinogenesis</description>
  </link>
  <link>
    <url>https://doi.org/10.1002/pon.860</url>
    <description>Empirical validation of the Insomnia Severity Index in cancer patients</description>
  </link>
  <link>
    <url>https://doi.org/10.1016/j.sleep.2018.11.022</url>
    <description>Disruption of sleep, sleep-wake activity rhythm, and nocturnal melatonin production in breast cancer patients undergoing adjuvant chemotherapy: a prospective cohort study</description>
  </link>
  <link>
    <url>https://s3.eu-west-2.amazonaws.com/www.hra.nhs.uk/media/documents/hra-mhra-econsent-statement-sept-18.pdf</url>
    <description>Joint statement on seeking consent by electronic methods</description>
  </link>
  <link>
    <url>http://www.hra-decisiontools.org.uk/consent/</url>
    <description>Consent and Participant Information Guidance</description>
  </link>
  <link>
    <url>https://doi.org/10.1177/1460458216656472</url>
    <description>A randomised controlled pilot study of CBT-I Coach: Feasibility, acceptability, and potential impact of a mobile phone application for patients in cognitive behavioural therapy for insomnia</description>
  </link>
  <link>
    <url>https://statulator.com/SampleSize/ss1P.html</url>
    <description>Sample Size Calculator for Estimating a Single Proportion</description>
  </link>
  <link>
    <url>https://doi.org/10.1007/978-3-540-89350-9_6</url>
    <description>Construction and Evaluation of a User Experience Questionnaire</description>
  </link>
  <reference>
    <citation>Ruel S, Ivers H, Savard MH, Gouin JP, Lemieux J, Provencher L, Caplette-Gingras A, Bastien C, Morin CM, Couture F, Savard J. Insomnia, immunity, and infections in cancer patients: Results from a longitudinal study. Health Psychol. 2020 May;39(5):358-369. doi: 10.1037/hea0000811. Epub 2019 Dec 19.</citation>
    <PMID>31855038</PMID>
  </reference>
  <reference>
    <citation>Kwak A, Jacobs J, Haggett D, Jimenez R, Peppercorn J. Evaluation and management of insomnia in women with breast cancer. Breast Cancer Res Treat. 2020 Jun;181(2):269-277. doi: 10.1007/s10549-020-05635-0. Epub 2020 Apr 20. Review.</citation>
    <PMID>32314110</PMID>
  </reference>
  <reference>
    <citation>Fleming L, Randell K, Stewart E, Espie CA, Morrison DS, Lawless C, Paul J. Insomnia in breast cancer: a prospective observational study. Sleep. 2019 Mar 1;42(3). pii: zsy245. doi: 10.1093/sleep/zsy245.</citation>
    <PMID>30521041</PMID>
  </reference>
  <reference>
    <citation>Fontes F, Pereira S, Costa AR, Gonçalves M, Lunet N. The impact of breast cancer treatments on sleep quality 1 year after cancer diagnosis. Support Care Cancer. 2017 Nov;25(11):3529-3536. doi: 10.1007/s00520-017-3777-6. Epub 2017 Jun 16.</citation>
    <PMID>28623402</PMID>
  </reference>
  <reference>
    <citation>Fortner BV, Stepanski EJ, Wang SC, Kasprowicz S, Durrence HH. Sleep and quality of life in breast cancer patients. J Pain Symptom Manage. 2002 Nov;24(5):471-80.</citation>
    <PMID>12547047</PMID>
  </reference>
  <reference>
    <citation>Hajj A, Hachem R, Khoury R, Nehme T, Hallit S, Nasr F, Karak FE, Chahine G, Kattan J, Khabbaz LR. Clinical and Genetic Factors Associated With the Breast Cancer-Related Sleep Disorders: The &quot;CAGE-Sleep&quot; Study-A Cross-Sectional Study. J Pain Symptom Manage. 2021 Sep;62(3):e46-e55. doi: 10.1016/j.jpainsymman.2021.02.022. Epub 2021 Feb 22.</citation>
    <PMID>33631331</PMID>
  </reference>
  <reference>
    <citation>Savard J, Ivers H, Villa J, Caplette-Gingras A, Morin CM. Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. J Clin Oncol. 2011 Sep 10;29(26):3580-6. doi: 10.1200/JCO.2010.33.2247. Epub 2011 Aug 8.</citation>
    <PMID>21825267</PMID>
  </reference>
  <reference>
    <citation>Brzecka A, Sarul K, Dyła T, Avila-Rodriguez M, Cabezas-Perez R, Chubarev VN, Minyaeva NN, Klochkov SG, Neganova ME, Mikhaleva LM, Somasundaram SG, Kirkland CE, Tarasov VV, Aliev G. The Association of Sleep Disorders, Obesity and Sleep-Related Hypoxia with Cancer. Curr Genomics. 2020 Sep;21(6):444-453. doi: 10.2174/1389202921999200403151720. Review.</citation>
    <PMID>33093806</PMID>
  </reference>
  <reference>
    <citation>Palesh O, Aldridge-Gerry A, Zeitzer JM, Koopman C, Neri E, Giese-Davis J, Jo B, Kraemer H, Nouriani B, Spiegel D. Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep. 2014 May 1;37(5):837-42. doi: 10.5665/sleep.3642.</citation>
    <PMID>24790261</PMID>
  </reference>
  <reference>
    <citation>Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol. 2001 Feb 1;19(3):895-908. Review.</citation>
    <PMID>11157043</PMID>
  </reference>
  <reference>
    <citation>Marion LP, Ivers H, Savard J. Feasibility of a Preventive Intervention for Insomnia in Women with Breast Cancer Receiving Chemotherapy. Behav Sleep Med. 2021 Jan-Feb;19(1):70-82. doi: 10.1080/15402002.2019.1707203. Epub 2019 Dec 24.</citation>
    <PMID>31873040</PMID>
  </reference>
  <reference>
    <citation>O'Donnell JF. Insomnia in cancer patients. Clin Cornerstone. 2004;6 Suppl 1D:S6-14. Review.</citation>
    <PMID>15675652</PMID>
  </reference>
  <reference>
    <citation>Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001 Jul;2(4):297-307.</citation>
    <PMID>11438246</PMID>
  </reference>
  <reference>
    <citation>Carney CE, Buysse DJ, Ancoli-Israel S, Edinger JD, Krystal AD, Lichstein KL, Morin CM. The consensus sleep diary: standardizing prospective sleep self-monitoring. Sleep. 2012 Feb 1;35(2):287-302. doi: 10.5665/sleep.1642.</citation>
    <PMID>22294820</PMID>
  </reference>
  <reference>
    <citation>Horsch CH, Lancee J, Griffioen-Both F, Spruit S, Fitrianie S, Neerincx MA, Beun RJ, Brinkman WP. Mobile Phone-Delivered Cognitive Behavioral Therapy for Insomnia: A Randomized Waitlist Controlled Trial. J Med Internet Res. 2017 Apr 11;19(4):e70. doi: 10.2196/jmir.6524.</citation>
    <PMID>28400355</PMID>
  </reference>
  <reference>
    <citation>Kang SG, Kang JM, Cho SJ, Ko KP, Lee YJ, Lee HJ, Kim L, Winkelman JW. Cognitive Behavioral Therapy Using a Mobile Application Synchronizable With Wearable Devices for Insomnia Treatment: A Pilot Study. J Clin Sleep Med. 2017 Apr 15;13(4):633-640. doi: 10.5664/jcsm.6564.</citation>
    <PMID>28162145</PMID>
  </reference>
  <reference>
    <citation>Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 Dec;20(10):1727-36. doi: 10.1007/s11136-011-9903-x. Epub 2011 Apr 9.</citation>
    <PMID>21479777</PMID>
  </reference>
  <reference>
    <citation>Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat. 1999 May;55(2):189-99.</citation>
    <PMID>10481946</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To be confirmed whether the individual participant data will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

